Pandey S, Wohland T
Biophys J. 2024; 123(21):3736-3749.
PMID: 39340155
PMC: 11560307.
DOI: 10.1016/j.bpj.2024.09.022.
Sampsonas F, Bosgana P, Bravou V, Tzouvelekis A, Dimitrakopoulos F, Kokkotou E
Genes (Basel). 2024; 15(7).
PMID: 39062713
PMC: 11276289.
DOI: 10.3390/genes15070934.
Bai X, Sun P, Wang X, Long C, Liao S, Dang S
Cell Discov. 2023; 9(1):18.
PMID: 36781849
PMC: 9925823.
DOI: 10.1038/s41421-023-00523-5.
Schramm F, Schaefer L, Wygrecka M
Cells. 2022; 11(6).
PMID: 35326439
PMC: 8947373.
DOI: 10.3390/cells11060986.
Brown M, Ried T
Cancers (Basel). 2022; 14(3).
PMID: 35159051
PMC: 8834070.
DOI: 10.3390/cancers14030784.
Coordinated dysregulation of cancer progression by the HER family and p21-activated kinases.
Kumar R, Paul A, Amjesh R, George B, Pillai M
Cancer Metastasis Rev. 2020; 39(3):583-601.
PMID: 32820388
DOI: 10.1007/s10555-020-09922-6.
A kinase inhibitor screen reveals protein kinase C-dependent endocytic recycling of ErbB2 in breast cancer cells.
Bailey T, Luan H, Tom E, Bielecki T, Mohapatra B, Ahmad G
J Biol Chem. 2014; 289(44):30443-30458.
PMID: 25225290
PMC: 4215227.
DOI: 10.1074/jbc.M114.608992.
Heregulin negatively regulates transcription of ErbB2/3 receptors via an AKT-mediated pathway.
Awasthi S, Hamburger A
J Cell Physiol. 2014; 229(11):1831-41.
PMID: 24692179
PMC: 4408997.
DOI: 10.1002/jcp.24637.
Evaluation of the antitumor activity of dacomitinib in models of human bladder cancer.
Grivas P, Day K, Karatsinides A, Paul A, Shakir N, Owainati I
Mol Med. 2013; 19:367-76.
PMID: 24166682
PMC: 3883970.
DOI: 10.2119/molmed.2013.00108.
HER2/NEU GENE EXPRESSION PRODUCTS EVALUATED WITH SUPERPARAMAGNETIC, GENETICALLY ENGINEERED ANTIBODIES.
Malecki M
Proc S Dak Acad Sci. 2013; 86:297-308.
PMID: 23293401
PMC: 3535833.
Proprotein convertase PC7 enhances the activation of the EGF receptor pathway through processing of the EGF precursor.
Rousselet E, Benjannet S, Marcinkiewicz E, Asselin M, Lazure C, Seidah N
J Biol Chem. 2011; 286(11):9185-95.
PMID: 21209099
PMC: 3059027.
DOI: 10.1074/jbc.M110.189936.
Dual inhibition of both the epidermal growth factor receptor and erbB2 effectively inhibits the promotion of skin tumors during two-stage carcinogenesis.
Kiguchi K, Kitamura T, Moore T, Rumi M, Chang H, Treece D
Cancer Prev Res (Phila). 2010; 3(8):940-52.
PMID: 20682802
PMC: 2940063.
DOI: 10.1158/1940-6207.CAPR-10-0010.
Fatty acid-binding protein 5 and PPARbeta/delta are critical mediators of epidermal growth factor receptor-induced carcinoma cell growth.
Kannan-Thulasiraman P, Seachrist D, Mahabeleshwar G, Jain M, Noy N
J Biol Chem. 2010; 285(25):19106-15.
PMID: 20424164
PMC: 2885189.
DOI: 10.1074/jbc.M109.099770.
Human rhomboid family-1 gene RHBDF1 participates in GPCR-mediated transactivation of EGFR growth signals in head and neck squamous cancer cells.
Zou H, Thomas S, Yan Z, Grandis J, Vogt A, Li L
FASEB J. 2008; 23(2):425-32.
PMID: 18832597
PMC: 2638965.
DOI: 10.1096/fj.08-112771.
Clathrin-independent endocytosis of ErbB2 in geldanamycin-treated human breast cancer cells.
Barr D, Ostermeyer-Fay A, Matundan R, Brown D
J Cell Sci. 2008; 121(Pt 19):3155-66.
PMID: 18765569
PMC: 2707784.
DOI: 10.1242/jcs.020404.
A review of lapatinib ditosylate in the treatment of refractory or advanced breast cancer.
Nelson M, Dolder C
Ther Clin Risk Manag. 2008; 3(4):665-73.
PMID: 18472989
PMC: 2374939.
Femara and the future: tailoring treatment and combination therapies with Femara.
Ellis M, Ma C
Breast Cancer Res Treat. 2007; 105 Suppl 1:105-15.
PMID: 17912640
PMC: 2001220.
DOI: 10.1007/s10549-007-9697-2.
EGFR, HER2 and VEGF pathways: validated targets for cancer treatment.
Press M, Lenz H
Drugs. 2007; 67(14):2045-75.
PMID: 17883287
DOI: 10.2165/00003495-200767140-00006.
Mutational activation of ErbB family receptor tyrosine kinases: insights into mechanisms of signal transduction and tumorigenesis.
Riese 2nd D, Gallo R, Settleman J
Bioessays. 2007; 29(6):558-65.
PMID: 17508401
PMC: 2789424.
DOI: 10.1002/bies.20582.
Extracellular domains drive homo- but not hetero-dimerization of erbB receptors.
Ferguson K, Darling P, Mohan M, Macatee T, Lemmon M
EMBO J. 2000; 19(17):4632-43.
PMID: 10970856
PMC: 302059.
DOI: 10.1093/emboj/19.17.4632.